FDA wants warning on some acetaminophen drugs; Lupin to make Ranexa generic; Shire settles age discrimination lawsuit;

@FiercePharma: Tension rises for pharma in China as court reportedly fines J&J, officials visit Sanofi. ICYMI yesterday | Follow @FiercePharma

@CarlyHFierce: More bribery allegations in China, these ones against Baxter (and just now surfacing from last year). News | Follow @CarlyHFierce

> CVS Caremark ($CVS) says it will pay a $20 million civil penalty to settle SEC allegations that it made inappropriate public disclosures in 2011 about problems in some units. Story

> Companies that sell prescription acetaminophen will be required to add a warning about the risk of potentially deadly rashes and blistering of the skin, the FDA said Thursday. News

> Mylan ($MYL) has let the markets know that it expects is sales to fall at the low end of its 2013 forecast of $7 billion to $7.4 billion. Report

> Indian generics maker Lupin says the FDA has approved its generic of Gilead Sciences' ($GILD) heart drug, Ranexa. More

Medical Device News

@FierceMedDev: Trending on FierceMedicalDevices.com: Covidien watches profits slide after kicking drugs. Article | Follow @FierceMedDev

@MarkHFierce: House Republican freshmen are pressing hard for a vote on a device tax repeal bill. Item | Follow @MarkHFierce

@DamianFierce: Now the Senate is getting in on the push to spare FDA user fees from sequester cuts. Story | Follow @DamianFierce

@MichaelGFierce: Trending on FierceDrugDelivery.com: Swedish team creates 'impossible' record-breaking drug delivery material. Article | Follow @MichaelGFierce

> Smith & Nephew has $1.5B and eyes on M&A. More

> J&J's DePuy, fearing fracture or limb-loss risks, recalls orthopedic implant part. News

> Report: ICU Medical nears sale that could top $1B. Article

Biotech News

@FierceBiotech: Industry Voices: The Zero-Person Biotech Company. Item | Follow @FierceBiotech

@JohnCFierce: Biotech's IPO boom extends its streak through a blistering July. Report | Follow @JohnCFierce

@RyanMFierce: Didn't take the lawyers long to start fishing for angry Optimer shareholders after Cubist buyout announced Tuesday. Release | Follow @RyanMFierce

@EmilyMFierce: NIH team sees diabetes drug as a possible tool for extending life. Story | Follow @EmilyMFierce

> Survey: Americans say cancer should be top priority for medical research. Story

> Stem cell transplants show potential in patients with extremely rare brain disease. More

> Baxter caught up in China bribery scandal. Item

And Finally... Shire ($SHPG) has settled an age discrimination lawsuit by the former head of its Regenerative Medicine unit. Story

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.